Design, development and evaluation of immediate release gliclazide tablets

The aim of the current study was the design, development and optimization of oral immediate release solid dosage forms of gliclazide tablets, intended for rapid action within 30 min, formulated and optimized by in vitro drug release method comparing with reference tablet Diamicron (Servier Lab.). For fast breakdown and rapid dissolution of tablets three different disintegrants (sodium starch glycolate, kollidone CL, and dried maize starch) were used with same percentage (2 %) in the formulations; sodium starch glycolate provide very fast release of gliclazide from tablets in pH 7.4. Two different compression methods, direct compression and wet granulation, were employed in the study. The in vitro drug release profile was better for directly compressed gliclazide tablets, but the flow properties of gliclazide were very poor, which causes high weight variation. Wet granulation method provided tablets of good physical parameters: two types of tablets with different hardness (8-10 kg/cm2 and 5-7 kg/cm2 ) were prepared to observe the effect of compressional forces on drug dissolution and the later one exhibits short disintegration time and rapid dissolution of gliclazide. Friability and weight variation were found within the acceptable range. Incorporation of anionic surfactant in combination with sodium starch glycolate or kollidone CL in the formulation the dissolution rate. In comparison with reference tablet, formulation containing 2 % sodium starch glycolate and 1 % sodium lauryl sulphate with other excipients as lactose, microcrystalline cellulose, povidone K-30, Mg stearate and colloidal silicon dioxide provide better dissolution. Shelf life of the formulated tablets were determined by utilizing stress condition (40 °C and 75 % Relative humidity for 3 months) and found more than 2.5 year in room condition.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Design, development and evaluation of immediate release gliclazide tablets

The aim of the current study was the design, development and optimization of oral immediate release solid dosage forms of gliclazide tablets, intended for rapid action within 30 min, formulated and optimized by in vitro drug release method comparing with reference tablet Diamicron (Servier Lab.). For fast breakdown and rapid dissolution of tablets three different disintegrants (sodium starch glycolate, kollidone CL, and dried maize starch) were used with same percentage (2 %) in the formulations; sodium starch glycolate provide very fast release of gliclazide from tablets in pH 7.4. Two different compression methods, direct compression and wet granulation, were employed in the study. The in vitro drug release profile was better for directly compressed gliclazide tablets, but the flow properties of gliclazide were very poor, which causes high weight variation. Wet granulation method provided tablets of good physical parameters: two types of tablets with different hardness (8-10 kg/cm2 and 5-7 kg/cm2 ) were prepared to observe the effect of compressional forces on drug dissolution and the later one exhibits short disintegration time and rapid dissolution of gliclazide. Friability and weight variation were found within the acceptable range. Incorporation of anionic surfactant in combination with sodium starch glycolate or kollidone CL in the formulation the dissolution rate. In comparison with reference tablet, formulation containing 2 % sodium starch glycolate and 1 % sodium lauryl sulphate with other excipients as lactose, microcrystalline cellulose, povidone K-30, Mg stearate and colloidal silicon dioxide provide better dissolution. Shelf life of the formulated tablets were determined by utilizing stress condition (40 °C and 75 % Relative humidity for 3 months) and found more than 2.5 year in room condition.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Design, development and evaluation of immediate release gliclazide tablets

The aim of the current study was the design, development and optimization of oral immediate release solid dosage forms of gliclazide tablets, intended for rapid action within 30 min, formulated and optimized by in vitro drug release method comparing with reference tablet Diamicron (Servier Lab.). For fast breakdown and rapid dissolution of tablets three different disintegrants (sodium starch glycolate, kollidone CL, and dried maize starch) were used with same percentage (2 %) in the formulations; sodium starch glycolate provide very fast release of gliclazide from tablets in pH 7.4. Two different compression methods, direct compression and wet granulation, were employed in the study. The in vitro drug release profile was better for directly compressed gliclazide tablets, but the flow properties of gliclazide were very poor, which causes high weight variation. Wet granulation method provided tablets of good physical parameters: two types of tablets with different hardness (8-10 kg/cm2 and 5-7 kg/cm2 ) were prepared to observe the effect of compressional forces on drug dissolution and the later one exhibits short disintegration time and rapid dissolution of gliclazide. Friability and weight variation were found within the acceptable range. Incorporation of anionic surfactant in combination with sodium starch glycolate or kollidone CL in the formulation the dissolution rate. In comparison with reference tablet, formulation containing 2 % sodium starch glycolate and 1 % sodium lauryl sulphate with other excipients as lactose, microcrystalline cellulose, povidone K-30, Mg stearate and colloidal silicon dioxide provide better dissolution. Shelf life of the formulated tablets were determined by utilizing stress condition (40 °C and 75 % Relative humidity for 3 months) and found more than 2.5 year in room condition.Colegio de Farmacéuticos de la Provincia de Buenos Aire

Effect of Propranolol on Functional Connectivity in Autism Spectrum Disorder—A Pilot Study

A decrease in interaction between brain regions is observed in individuals with autism spectrum disorder (ASD), which is believed to be related to restricted neural network access in ASD. Propranolol, a beta-adrenergic antagonist, has revealed benefit during performance of tasks involving flexibility of access to networks, a benefit also seen in ASD. Our goal was to determine the effect of propranolol on functional connectivity in ASD during a verbal decision making task as compared to nadolol, thereby accounting for the potential spurious fMRI effects due to peripheral hemodynamic effects of propranolol. Ten ASD subjects underwent fMRI scans after administration of placebo, propranolol or nadolol, while performing a phonological decision making task. Comparison of functional connectivity between pre-defined ROI-pairs revealed a significant increase with propranolol compared to nadolol, suggesting a potential imaging marker for the cognitive effects of propranolol in ASD

Many LINE1 elements contribute to the transcriptome of human somatic cells

Over 600 LINE 1 elements are shown to be transcribed in humans; 400 of these are full-length elements in the reference genome